Opus Genetics (IRD) Operating Margin (2010 - 2026)
Opus Genetics (IRD) reported Operating Margin of 665.92% for Q1 2026, down 43872.0% year-over-year from N/an in Q1 2025, and down 124.73% on a QoQ basis from 296.33% in Q4 2025.
Opus Genetics (IRD) has 8 years of Operating Margin data on file, last reported at 665.92% in Q1 2026.
- Quarterly Operating Margin fell 43872.0% year-over-year to 665.92% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 359.13% (up 11187.0% YoY) and the FY2025 annual result came in at 271.9%, up 29282.0% from the prior year.
- Operating Margin retreated to 665.92% in Q1 2026 per IRD's latest filing, from 296.33% in the prior quarter.
- Across five years, Operating Margin topped out at 85.85% in Q4 2022 and bottomed at 883.98% in Q4 2024.
- The 5-year median for Operating Margin is 302.67% (2025), against an average of 338.42%.
- The widest annual swing landed in 2024, when Operating Margin plunged 60224 bps; it then jumped 58766 bps in 2025.
- Tracing IRD's Operating Margin over 5 years: stood at 85.85% in 2022, then tumbled by 474 bps to 321.05% in 2023, then sank by 175 bps to 883.98% in 2024, then jumped by 66 bps to 296.33% in 2025, then sank by 125 bps to 665.92% in 2026.
- Per Business Quant, the three latest IRD Operating Margin figures stand at 665.92% (Q1 2026), 296.33% (Q4 2025), and 269.93% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.43% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 38.10% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 17.83% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 23.02% |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | -665.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -665.92% |
| Dec 31, 2025 | -296.33% |
| Sep 30, 2025 | -269.93% |
| Jun 30, 2025 | -309.02% |
| Mar 31, 2025 | -227.21% |
| Dec 31, 2024 | -883.98% |
| Sep 30, 2024 | -207.11% |
| Jun 30, 2024 | -748.92% |
| Mar 31, 2024 | -450.50% |
| Dec 31, 2023 | -321.05% |
| Sep 30, 2023 | 53.51% |
| Jun 30, 2023 | -146.68% |
| Mar 31, 2023 | -350.54% |
| Dec 31, 2022 | 85.85% |
| Sep 30, 2021 | -865.44% |
| Jun 30, 2021 | -7,137.00% |
| Mar 31, 2020 | -237.83% |
| Jun 30, 2010 | -17,008.07% |